A few days but but what a cracker!!! Just what i had hoped-for. Strong growth across rev (up 60%!), EBITDA, EBIT and NPAT grew by 52.2%. Despite massive increase in CAPEX, strong AUD, rising labour costs, margins have effectively been maintained at over 23%. Operating cashflow reduced due to capex but CR ensured low debt at only 12.7%. Also confirmation the Brandrill aquisition (which i urger ASL to make 2 yrs ago) has proved a great success.
The important thing is that ASL is able to increase BOTH rig utilisation rate and profits on each drill rig contracted out. This is a multiple effect and should not be under-estimated.
The only downside (in short term) is that due to CR the EPS has not risen as fast as other metrics. EPS up 14.4% to 23.7c. Final div up only half-cent to 6.5c ffr.
But oulook is positive. Company forecast rev to rise 20% and hit 1 Billion mark. I expect no more CR and as new acquisitions rapidly produce income (esp mineral analytical labs) that EPS will rise 20% in FY12. Am expecting total divs in FY12 of 14.5c (6.5+8). Assuming I'm right what PE does one apply to a company able to grow earnings at this rate?
- Forums
- ASX - By Stock
- PRN
- results for fy12
results for fy12, page-6
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
98.5¢ |
Change
-0.010(1.01%) |
Mkt cap ! $923.8M |
Open | High | Low | Value | Volume |
99.0¢ | $1.00 | 98.5¢ | $1.075M | 1.084M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 30129 | 98.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 30129 | 0.980 |
3 | 14444 | 0.975 |
2 | 59236 | 0.970 |
3 | 110890 | 0.965 |
7 | 106026 | 0.960 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 20000 | 1 |
0.995 | 35537 | 2 |
1.000 | 52785 | 4 |
1.005 | 7144 | 1 |
1.010 | 51300 | 3 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
PRN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online